We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 0.88% | 28.50 | 28.50 | 29.00 | 28.75 | 28.25 | 28.25 | 2,637,345 | 16:35:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 48.48M | -776k | -0.0011 | -261.36 | 194.08M |
TIDMHVO
RNS Number : 3908C
hVIVO plc
13 April 2017
For immediate release 7.00am: 13 April 2017
HVIVO PLC
("hVIVO" or the "Company")
Trading Update
hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, announces a trading update regarding the accounting treatment of the Company's joint venture investment in Imutex Limited ("Imutex"). This reverses the change in accounting treatment for Imutex announced on 21 September 2016 and returns to the original position announced on 22 April 2016 to recognise the GBP5.5 million FLU-v Phase IIa clinical study as revenue as the work is completed.
This aligns and makes consistent the accounting treatment of hVIVO's equity investments in PrEP Biopharm Limited ("PrEP") and Imutex. It is only a revenue measurement and presentation difference for Imutex with no net effect to hVIVO's financials, no change in underlying economic value, no change in net income and no cash flow impact. Accordingly, hVIVO's revenue expectation for the year ended 31 December 2016 increases for the revenue from the FLU-v clinical study.
On 22 April 2016 hVIVO announced its joint venture investment in Imutex with the SEEK Group ("SEEK") to develop vaccines against influenza (flu) and mosquito-borne diseases like Zika. hVIVO acquired a 49% equity stake in Imutex for GBP7.0 million in consideration and SEEK contracted with hVIVO Services Limited to conduct a FLU-v Phase IIa clinical study for GBP5.5 million. Following the appointment of Ernst & Young LLP ("EY") as the Company's auditor on 28 December 2016, and as part of its maiden audit, EY conducted a detailed review of the accounting judgements and treatment of the Company's equity investments in PrEP and Imutex, which has led to this change in accounting treatment for Imutex.
The Company will announce its audited preliminary results for the year ended 31 December 2016 at 7.00am on Thursday 20 April 2017. hVIVO now expects to report revenue for the year ended 31 December 2016 of GBP19.9 million and a gross profit margin of 21.3%. In addition, the Company expects to report cash balances as at 31 December 2016 of GBP25.7 million.
Kym Denny, Chief Executive Officer, comments, "I look forward to announcing our 2016 prelims next week and communicating the significant steps we are making in our quest for precision medicines in respiratory and infectious disease. I am pleased that the question regarding accounting treatment of hVIVO's equity investments has been resolved and that we are able to align the accounting treatment of the PrEP and Imutex transactions."
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three First-In-Class therapies currently in development with a growing pre-clinical pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTSFDEEEFWSELL
(END) Dow Jones Newswires
April 13, 2017 02:00 ET (06:00 GMT)
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions